Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Allergan's Eyelash Enhancer Makes Your Blue Eyes Brown
- Allergan is hoping to turn its glaucoma drug, Lumigan, into a cosmetic treatment for longer eyelashes. Lumigan is currently approved only for preventing blindness. But it has one very odd side effect: patients’ eyelashes become longer when using it. Unsurprisingly, doctors are already using it off-label...
- Blog posts 2008-10-27
Additional Resources
- Allergan Announces FDA Approval of LUMIGAN® as First-Line Treatment for Elevated Eye Pressure in Open-Angle Glaucoma; Indication Expands Approved Uses of LUMIGAN® in the Management of Glaucoma
- IRVINE, Calif. -- Allergan, Inc. (NYSE:AGN) today announced that the United States Food and Drug Administration FDA has approved Allergan's once-daily prescription eye drop LUMIGANR bimatoprost ophthalmic solution 0.03% as a first-line treatment for elevated intraocular pressure IOP associated with open-angle glaucoma or ocular hypertension. The LUMIGANR first-line indication is...
- Research articles 2006-06-23
- Allergan Receives Approvable Letter for LUMIGAN — bimatoprost-timolol
- IRVINE, Calif. -- Allergan, Inc. (NYSE:AGN) today announced that the U.S. Food and Drug Administration FDA has issued an approvable letter for its LUMIGANR timolol combination product for glaucoma (bimatoprost 0.03 percent/timolol 0.05 percent ophthalmic solution). An approvable letter sets out the conditions that a company must meet in order...
- Research articles 2004-08-03
- The Pfizer-Allergan Deal Worst-Case Scenario
- CNBC Mad Money host Jim Cramer suggested recently that Pfizer ought to acquire Allergan, maker of Botox and Juvederm. Cramer is usually not worth listening to but this idea has some merit: A tie-up of the two companies has advantages for both. However, mergers don't always go as planned, so...
- Blog posts 2008-12-05
- FDA Approves First Prostamide — LUMIGAN — for Patients With Glaucoma; LUMIGAN Achieves Lower Target Intraocular Pressures in More Patients Than Timolol
- Business Editors
- Research articles 2001-03-16
- FDA approves Allergan's eyelash-growth drug
- The FDA has approved another indication for Allergan's seven-year old drug Lumigan bimatoprost. Doctors and patients noticed that the glaucoma treatment had the unusual side effect of lengthening and thickening eyelashes, leading several competitors to market products based on ingredients in Lumigan. Allergan has already sued a number of cosmetics...
- News items 2009-08-07
- Allergan's LUMIGAN Receives Positive Opinion for Approval in Europe
- Business Editors & Health/Medical Writers
- Research articles 2001-11-19
- Allergan Enters Into Settlement in Principle With Pharmacia and Columbia University Regarding All Lumigan Intellectual Property Disputes
- Business Editors
- Research articles 2002-10-24
- Allergan and Senju Pharmaceutical Sign Exclusive Licensing Agreement to Develop and Market LUMIGAN-R- in Japan
- Business Editors/Health/Medical Writers
- Research articles 2004-05-24
- Allergan offers glaucoma advice
- ALLERGAN, in a joint effort with Webb-Patterson Communications, is running an educational campaign designed to raise awareness of glaucoma and, in turn, drive sales of its Lumigan and Alphagan glaucoma treatments.
- Research articles 2003-06-01
- Allergan Receives Pan European License for GANFORT® from European Commission
- IRVINE, Calif. -- Allergan, Inc. (NYSE:AGN) today announced that it has received the license from the European Commission to market GANFORTR, Allergan's LUMIGANR/timolol combination product (bimatoprost/timolol ophthalmic solution) for the treatment of glaucoma, in the European Union.
- Research articles 2006-05-25
- Allergan Receives Positive Opinion for GANFORT® in European Union
- IRVINE, Calif. -- Allergan, Inc. (NYSE:AGN) today announced that the Committee for Medicinal Products for Human Use CHMP has recommended that the European Commission approve GANFORTR, Allergan's LUMIGANR/timolol combination product (bimatoprost/timolol ophthalmic solution) for the treatment of glaucoma. The CHMP opinion serves as the basis for a European Commission approval,...
- Research articles 2006-03-24
- The Allergan-Medicis Vanity Pharma Death Match Is About to Get Complicated
- Imagine your drug company has the following problems: A portfolio of expensive, discretionary cosmetic products that Medicare and Medicaid won't reimburse for; it's under investigation by the Department of Justice for alleged off-label promotion; the recession is crimping consumers' desire to spend money on non-essential drug products;...
- Blog posts 2008-09-08
- The GlaxoSmithKline-Allergan Deal Worst-Case Scenario
- Allergan's stock has risen on an item from DealReporter.com outlining acquisition discussions with GlaxoSmithKline. Allergan surged $5.41, or 13 percent, to $48.58, per Bloomberg, on the news. As usual, at BNET we ask: before the money gets spent, what's the worst-case scenario? The first...
- Blog posts 2009-03-25
- Ddmac Untitled Letters
- The following untitled letters were issued by the Centers for Drugs' Division of Drug Marketing, Advertising and Communications DDMAC. Copies are available from our RECORD-RETRIEVE service for $7 plus retrieval. Please reference the MACMIS ID # to order the company response. 10700W Allergan, Irvine, CA, June...
- Research articles 2001-08-13
- Is Allergan's Latisse Also a Cure for Baldness?
- Allergan believes it may have a cure for baldness in the form of Latisse/Lumigan, its glaucoma drug-cum-eyelash enhancer. EVP R&D Scott Whitcup told investors by Jim Edwards
- Blog posts 2009-08-11
- In Allergan's Search for Baldness Cure, Does the Stumptailed Macaque Hold the Key?
- There are few good indications to whether Allergan's Latisse could also cure male-pattern baldness. The stumptailed macaque pictured, a monkey that goes bald, may hold clue. BNET reported yesterday that Allergan is planning trials of Latisse (the eyelash-enhancing drug that was developed from glaucoma drug Lumigan) to see if it...
- Blog posts 2009-08-12
- << Previous
- page 1 of 1
- Next >>
Presented by the Premiere Rewards Gold Card from American Express